VitalSurface Microclimate Overlay
A Smarter Surface for Immobility Care
Patent Pending
VitalSurface Microclimate Overlay is a nextgeneration medical supportsurface technology designed to reduce the hidden drivers of pressure injury during extended bed care heat buildup, sweat, moisture, pressure duration, shear, heel loading, and patient discomfort.
The product is positioned as a Strykercompatible smart overlay or licensable technology module that adds nearsurface hydronic cooling/warming, alternating pressure redistribution, lowshear cover design, sealed infectioncontrol architecture, heel/calf offloading, sensor feedback, and careprotocol reporting to acutecare, ICU, longtermcare, and homehealth environments.
The recommended licensing target is Stryker, because Stryker already participates in the acutecare bed and pressureredistributing supportsurface market. The strategic pitch is not that Stryker lacks support surfaces; it is that VitalSurface extends the category from lowairloss microclimate management into active, closedloop thermal and pressurezone intelligence.
Pressure injuries remain a large clinical and economic burden. AHRQ reports that pressure ulcers affect approximately 2.5 million patients per year in the United States and cost the U.S. healthcare system $9.1 billion to $11.6 billion annually, with individual patientcare costs ranging from $20,900 to $151,700 per pressure ulcer.
The global pressureulcerprevention market is projected by Fortune Business Insights to grow from approximately $1.21 billion in 2026 to $1.69 billion by 2034, while broader pressureulcer treatment and hospitalbed markets are larger adjacent opportunities.
Product Vision
VitalSurface Microclimate Overlay
A Smarter Surface for Immobility Care
VitalSurface is a sealed medical overlay system with a disposable or single-patient-use microclimate coverlet and a reusable powered base layer. The product uses a near-surface hydronic pathway to provide controlled thermal management, with cooling across the sacral, back, torso, thigh, and calf regions and a separate warming zone at the feet.
The system is designed to manage
Risk Factor Product Response
Sustained pressure Alternating pressure chambers and load redistribution
Heat buildup Controlled cooling near the skincontact surface
Sweat and humidity Vaporpermeable coverlet and protected airflow / moisture pathway
Shear and friction Lowshear cover surface and repositioningfriendly materials
Heel pressure CalfLift and HeelFloat accessory geometry
Cold feet / discomfort Dedicated WarmStep footwarming zone
Nursing workflow Protocol presets, alarms, skincheck reminders, and usage logs
Infectioncontrol risk Disposable coverlet over sealed reusable barrier
Core Product Differentiation
Existing support surfaces already include air cells, alternating pressure, lowairloss airflow, lateral rotation, and turn assist. FDA regulation defines an alternatingpressure air flotation mattress as a medical mattress with multiple air cells that fill and empty in alternating patterns to automatically change body pressure distribution for prevention and treatment of bed sores; this device type is classified under 21 CFR 880.5550.
VitalSurface should differentiate itself through the following claims and capabilities
Existing Market Capability VitalSurface Upgrade
Low air loss removes some heat and moisture Closedloop cooling/warming with target thermal zones
Alternating pressure shifts body load Pressure cycling coordinated with thermal and humidity data
Lateral rotation assists repositioning, overlay level, microturn and pressure duration logic
Heel pads and gel zones reduce heel loading Integrated calflift and heelsuspension accessory system
Basic alarms and pump controls RiskTrace careprotocol reporting and data logging
Reusable mattress cover Disposable CleanSeal microclimate coverlet over sealed reusable overlay
Product Architecture
Main Components
Component Description
Reusable overlay body Sealed medicalgrade supportsurface layer containing pressure chambers, hydronic pathways, manifolds, sensors, and protective barriers
CleanSeal disposable coverlet Singlepatientuse or limiteduse vaporpermeable, fluidresistant patientcontact layer
Hydronic cooling/warming tubes Nearsurface sealed water/glycol pathway for controlled temperature distribution
ClimaCore control unit Pump, thermal module, valves, sensors, alarms, and user interface
PulseCell air chambers Alternating pressure cells for pressure redistribution
DryFlow vapor pathway Moisture and humidity management layer protected from liquid ingress
WarmStep foot zone Separate warming circuit for feet
SacraShield zone Enhanced sacral cooling and pressure redistribution
HeelFloat / CalfLift module Calf support geometry that unloads heels
RiskTrace reporting Tracks mode usage, alarms, pressurecycling history, and protocol compliance
InfectionControl Architecture
The product should not be designed as a perforated mattress with open holes into the mattress body. The correct architecture is a sealed overlay with a replaceable cover system.
Layer Function Reusable / Disposable
Patientcontact coverlet Comfort, vapor transfer, low shear Disposable or singlepatientuse
FluidBlock barrier Liquidresistant medical barrier Reusable
Hydronic thermal layer Cooling/warming pathways Reusable
Air chamber layer Alternating pressure support Reusable
Sensor layer Temperature, humidity, pressure, presence Reusable
Control unit Pump, valves, thermal control, alarms Reusable
This is essential because bodyfluid ingress into hospital mattresses is a known infectioncontrol concern. FDA guidance warns that damaged or worn mattress covers may allow blood and body fluids to enter the mattress core, creating contamination risk. ([AHRQ][1])
Target Customers
Primary Customers
Segment Reason for Need
Acutecare hospitals Pressureinjury prevention, nursing workload, documentation, patient comfort
ICUs High immobility, sweating, fever, sedation, ventilation, long bed duration
Longterm acutecare hospitals Extended immobility and higher pressureinjury risk
Skilled nursing facilities Highrisk eldercare population
Rehabilitation hospitals Patients with limited mobility and long bed exposure
Homehealth / hospice Longduration bed care, caregiver support, comfortfocused prevention
Strategic Licensing Target
Primary target Stryker
Stryker is a logical target because it already sells hospital beds, support surfaces, and pressure injury prevention systems. The licensing argument should be “VitalSurface adds active thermal microclimate intelligence to the supportsurface category, creating a premium upgrade path for Stryker’s existing hospitalbed and pressureredistribution ecosystem.”
Secondary Licensing / Strategic Targets
Company Strategic Fit
Hillrom / Baxter Hospital beds, connected beds, pressureinjury prevention
Arjo Pressureinjury prevention, lowairloss, turn assist, longtermcare surfaces
Joerns Healthcare Longtermcare and homecare support surfaces
Medline Large distribution channel, longtermcare and facility supply
Drive DeVilbiss Homecare and DME channel
Invacare / Etactype channels Homecare supportsurface distribution
Regulatory and Approval Strategy
Likely FDA Pathway
The pressure distribution and alternating pressure portions align with the existing FDA device category for alternating-pressure air flotation mattresses. FDA’s classification under 21 CFR 880.5550 covers mattresses with multiple air cells that fill and empty automatically to change pressure distribution for bedsore prevention and treatment.
However, VitalSurface adds
Hydronic cooling/warming
Temperature sensors
Software control recipes
Alarms
Disposable coverlet system
Potential humidity sensing
Potential reporting and compliance logs
Because of those features, the safest strategy is to plan for a Class II 510(k) pathway unless a regulatory consultant determines that a specific configuration is exempt. FDA’s productcode database includes alternating pressure airflotation mattresses under product code FNM, and FDA has prior 510(k) entries for powered low-air-loss mattress systems.
Required Regulatory Workstreams
Workstream Purpose
FDA product classification review Confirm predicate devices, product code, and claims strategy
510(k) strategy Establish substantial equivalence if required
Labeling review Avoid overclaiming prevention or treatment before trial evidence
Risk management ISO 14971 hazard analysis
Electrical safety IEC 606011 testing
EMC testing IEC 6060112
Software lifecycle IEC 62304
Usability / human factors IEC 62366
Biocompatibility ISO 10993 for patientcontact materials
Cleaning validation Hospital disinfectant compatibility and reprocessing protocol
Fluid ingress testing Coverlet and sealed barrier validation
Thermal safety testing Prevent burns, excessive cooling, condensation, and patient discomfort
Mechanical durability Bed articulation, patient load, cycling, leak, and fatigue testing
Regulatory Cost Estimate
Regulatory / Compliance Item Estimated Cost
Regulatory consulting and classification strategy $75,000–$200,000
Predicate and 510(k) preparation $150,000–$400,000
Electrical safety and EMC testing $150,000–$450,000
Software documentation and verification $250,000–$750,000
Biocompatibility and material testing $75,000–$250,000
Cleaning / disinfection validation $75,000–$250,000
Human factors validation $150,000–$500,000
Thermal and fluidingress safety testing $150,000–$500,000
Total regulatory / approval budget $1.075M–$3.3M
Clinical Trial and Validation Strategy
Trial Positioning
The product should initially avoid claiming that it independently prevents all pressure injuries.
The stronger first claim is “VitalSurface assists with pressure redistribution, skininterface microclimate management, heel offloading, and extended bed care comfort.” Then clinical evidence can support stronger claims over time.
Recommended Trial Sequence
Phase Scope Objective Estimated Cost
Bench validation Laboratory pressure, thermal, humidity, durability, fluid ingress Prove technical safety and performance $300,000–$900,000
Usability study Nurses, woundcare staff, biomedical engineering Confirm safe setup, cleaning, alarms, and workflow $150,000–$500,000
Healthy volunteer study 20–40 subjects Comfort, skin temperature, humidity, interface pressure mapping $250,000–$750,000
Pilot clinical study 50–150 highrisk patients Feasibility, comfort, microclimate data, adverse events $750,000–$2.5M
Pivotal / comparative study 300–1,000 patients Compare to standard support surfaces for pressureinjury outcomes $2.5M–$8M
Postmarket registry Multisite hospital deployment Realworld evidence, HAPI reduction, compliance data $500,000–$2M annually
Key Trial Endpoints
Endpoint Type Examples
Technical endpoints Interface temperature, humidity, pressure redistribution, heel offloading
Clinical endpoints Incidence of stage 1+ pressure injuries, sacral injury rate, heel injury rate
Comfort endpoints Sleep comfort, thermal comfort, perceived sweating, pain/discomfort
Workflow endpoints Nursing setup time, repositioning support, skincheck compliance
Economic endpoints Avoided pressureinjury cost, reduced woundcare burden, reduced litigation exposure
Safety endpoints Thermal discomfort, skin cooling reaction, condensation, leaks, alarms, cleaning failures
Development Roadmap
Phase 1 Concept, IP, and Feasibility
Duration 3–6 months
Estimated Cost $150,000–$400,000
Deliverables
Patent search and provisional patent filing
Product requirements document
Strykercompatible design language
Thermal pathway architecture
Pressure chamber architecture
Infectioncontrol architecture
Preliminary regulatory classification
Early hospital customer discovery
Phase 2 Engineering Prototype
Duration 6–12 months
Estimated Cost $750,000–$2.0M
Deliverables
Functional hydronic cooling/warming overlay
Air pressure chamber prototype
Disposable coverlet samples
Thermal sensor network
Basic controller and interface
Bench pressure mapping
Thermal performance testing
Fluidbarrier screening
Early nurse/woundcare feedback
Phase 3 Alpha Medical Prototype
Duration 9–15 months
Estimated Cost $1.5M–$4.0M
Deliverables
Hospital-grade prototype units
Cleanable control unit
Sealed manifolds
Replaceable coverlet system
Alarm logic
Usability documentation
Risk Management file
Software verification plan
Initial design for manufacturing review
Phase 4 Verification, Validation, and Pilot Study
Duration 12–24 months
Estimated Cost $3.0M–$8.0M
Deliverables
Verification and validation testing
Biocompatibility testing
Electrical safety and EMC testing
Cleaning validation
Human factors validation
Pilot clinical study
510(k) package if required
Manufacturing process validation
Phase 5 Commercial Launch / Licensing Transfer
Duration 12–18 months
Estimated Cost $3.0M–$10.0M depending on launch scale
Deliverables
Production tooling
Supply chain qualification
Quality system transfer
Launch inventory
Sales training package
Service manuals
Hospital pilot deployments
Postmarket data capture
Tooling and Equipment Plan
SoftGoods and Overlay Manufacturing
Tooling / Equipment Purpose Estimated Cost
RF welding system Weld TPU / coated textile air chambers $150,000–$500,000
RF welding dies Custom chamber geometry and sealed pathways $75,000–$300,000
CNC fabric cutting table Precision cutting of cover, barrier, and bladder materials $75,000–$250,000
Heatsealing fixtures Sealing disposable coverlet and fluid barrier components $50,000–$200,000
Leaktest fixtures Pressure decay testing for chambers and tubing $75,000–$250,000
Hydronic tube placement fixtures Repeatable tube layout near top surface $50,000–$200,000
Manifold assembly tooling Fluid and air pathway assembly $75,000–$300,000
Coverlet converting tooling Disposable cover production $100,000–$500,000
Control Unit and Electronics Manufacturing
Tooling / Equipment Purpose Estimated Cost
Injection molds for control housing Pump / controller enclosure $150,000–$600,000
Injection molds for manifolds and connectors Fluid and air interface components $100,000–$400,000
PCB assembly fixtures Sensor and control electronics $50,000–$200,000
Pump / valve test stands Flow and pressure verification $75,000–$300,000
Thermal module test rig Cooling/warming performance verification $100,000–$350,000
Final assembly fixtures Repeatable product assembly $100,000–$500,000
Endofline functional tester Pressure, thermal, alarms, sensors $150,000–$600,000
Quality and Validation Equipment
Equipment Purpose Estimated Cost
Thermal chamber Temperature/humidity testing $100,000–$350,000
Pressure mapping system Interface pressure validation $50,000–$200,000
Articulation fatigue test bed Repeated bedposition cycling $75,000–$300,000
Cleaning / wipe testing setup Disinfection durability $50,000–$150,000
Fluidingress test fixtures Urine/blood/bodyfluid simulation $50,000–$200,000
Data acquisition system Sensor and control verification $50,000–$200,000
Total Tooling and Equipment Estimate
Launch Scale Estimated Tooling / Equipment Budget
Prototype / pilot build $500,000–$1.5M
Lowvolume commercial launch $2.0M–$5.0M
Fullscale manufacturing $6.0M–$15.0M
Stryker integrated manufacturing Lower DTC capital need; Stryker absorbs or shares tooling
Materials and Bill of Materials
Estimated COGS by Product Version
Component Overlay Version COGS ICU Premium Version COGS
Sealed overlay body $350–$700 $600–$1,200
Hydronic tubing / manifolds $120–$300 $250–$600
Air chambers $150–$400 $250–$700
Sensor package $100–$300 $250–$700
Control unit $450–$1,100 $900–$2,000
Pump / valves $250–$700 $500–$1,300
Thermal module $300–$900 $700–$1,800
Disposable coverlet starter kit $40–$120 $60–$150
Packaging / manuals $50–$150 $75–$200
Assembly and QA $200–$600 $400–$1,000
Estimated total COGS $1,960–$5,270 $3,985–$11,650
Target Pricing
Product Target ASP
VitalSurface Overlay, standard acutecare $6,995–$9,995
VitalSurface ICU / highrisk version $11,995–$19,995
Stryker integrated premium bed option $8,000–$15,000 addon
CleanSeal disposable coverlet $65–$150 each
HeelFloat / CalfLift accessory $395–$995
Service / annual maintenance plan $750–$1,500 per unit annually
USA Market Opportunity
Market Drivers
The U.S. opportunity is strong because pressure injuries create
-
Direct treatment cost
-
Hospital-acquired condition penalties
-
Litigation exposure
-
Nursing workload
-
Infection risk
-
Patient suffering
-
Family dissatisfaction
-
Long-term care liability
AHRQ reports pressure ulcers cost the U.S. healthcare system $9.1B–$11.6B annually and are associated with more than 17,000 lawsuits annually, making prevention financially meaningful for hospitals and care facilities.
Addressable U.S. Segments
Segment Estimated Fit
ICU beds Highest clinical need and highest willingness to pay
Medsurg highrisk beds Largevolume opportunity
Longterm acutecare hospitals Strong fit for extended immobility
Skilled nursing facilities High need, lower price sensitivity than home but more costconstrained than ICU
Hospice / palliative care Comfortfocused version
Home DME Laterstage simplified model
U.S. Sales Scenarios
Scenario Annual Units Average Selling Price Annual Product Revenue Coverlet / Service Revenue Total Annual Revenue
Pilot launch 500 $8,500 $4.25M $0.5M $4.75M
Early hospital adoption 2,500 $8,500 $21.25M $3M $24.25M
National niche adoption 10,000 $8,000 $80M $15M $95M
Stryker channel scale 25,000 $7,500 $187.5M $40M $227.5M
Mature U.S. penetration 50,000 $7,000 $350M $90M $440M
Global Sales Potential
The global pressureulcerprevention market is projected at approximately $1.21B in 2026 and $1.69B by 2034, according to Fortune Business Insights. ([Fortune Business Insights][2])
The global medicalbed market is much larger, estimated by Global Market Insights at $4.3B in 2025, growing to $7.4B by 2035, with acutecare beds representing a major share.
International Market Fit
Region Opportunity
North America Premium hospital systems, pressureinjury liability, early adoption
Western Europe Strong eldercare and hospitalquality systems
Japan / South Korea Aging population, high technology adoption
Gulf States Premium hospital infrastructure and medical modernization
Australia / New Zealand Highquality hospital care and agedcare need
Latin America Midtier version through distributor partnerships
India / Southeast Asia Longterm future opportunity with simplified lowercost model
Global Revenue Scenarios
Scenario Annual Units Blended ASP Product Revenue Coverlet / Service Revenue Total Annual Revenue
Conservative global adoption 5,000 $7,500 $37.5M $6M $43.5M
Moderate adoption 25,000 $7,000 $175M $35M $210M
Strong licensing adoption 75,000 $6,500 $487.5M $120M $607.5M
Global platform adoption 150,000 $6,000 $900M $250M $1.15B
Profit Model
Direct Manufacturing Model
Revenue Scenario Revenue Gross Margin Gross Profit Operating Expense EBITDA Estimate
Pilot $4.75M 45% $2.14M $5M–$8M Negative
Early adoption $24.25M 50% $12.13M $10M–$15M Breakeven to modest loss
National niche $95M 55% $52.25M $25M–$35M $17M–$27M
Stryker channel scale $227.5M 60% $136.5M $50M–$70M $66M–$86M
Global platform $1.15B 62% $713M $180M–$250M $463M–$533M
Licensing Model
The licensing model is cleaner and lower risk for DTCIntl / Design Team Collaboration because Stryker or another strategic partner would carry manufacturing, regulatory, clinical, sales, distribution, service, and hospital contracting costs.
Licensing Scenario Annual Net Sales Royalty Rate Annual Royalty
Early license launch $25M 5% $1.25M
National Stryker adoption $150M 5% $7.5M
Mature U.S. adoption $350M 5% $17.5M
Global adoption $750M 4.5% $33.75M
Global platform success $1.15B 4% $46M
Recommended Royalty Structure
Royalty Component Suggested Rate
Base IP royalty 3.0–5.0% of net sales
Milestone royalty kicker after clinical proof +0.5–1.0%
Disposable coverlet royalty 2.0–4.0%
Minimum annual royalty after launch $1M–$5M depending on territory
Upfront license fee $2M–$10M
Development milestone payments $5M–$25M total
Planting Foundations / youth R&D contribution 0.25–1.0% of net sales or fixed annual grant
FiveYear Financial Projection
LicensingFocused Model
Year Development Stage Net Sales Through Partner Royalty / Milestone Revenue Notes
Year 1 IP, prototype, Stryker pitch $0 $0–$2M Possible option agreement
Year 2 Engineering prototype / pilot units $0 $2M–$8M Development milestone
Year 3 Validation and pilot launch $5M–$15M $2M–$10M Limited hospital deployments
Year 4 U.S. commercial launch $50M–$125M $3M–$12M Royalty begins scaling
Year 5 U.S. expansion / global prep $150M–$300M $8M–$20M Coverlet revenue becomes important
Direct Commercialization Model
Year Revenue EBITDA Notes
Year 1 $0 $1M to $3M Prototype and IP
Year 2 $0–$1M $3M to $8M Engineering and validation
Year 3 $2M–$8M $5M to $12M Pilot deployments
Year 4 $20M–$50M $2M to +$8M Early sales
Year 5 $75M–$150M $10M–$40M Scaled manufacturing and service revenue
Funding Requirement
Minimum Licensing Package Budget
Use of Funds Estimated Cost
IP and patent strategy $150,000–$500,000
Engineering feasibility prototype $500,000–$1.5M
Industrial design and Strykerstyle demo assets $150,000–$400,000
Regulatory strategy $100,000–$300,000
Bench testing $250,000–$750,000
Clinical advisor / woundcare board $100,000–$300,000
Business development / licensing package $100,000–$300,000
Total licensingready budget $1.35M–$4.05M
Full Development Budget Before Commercial Launch
Category Estimated Cost
Product development $3M–$8M
Tooling and equipment $2M–$8M
Regulatory and compliance $1M–$3.3M
Clinical studies $3M–$10M
Quality system $500,000–$2M
Launch inventory $2M–$8M
Sales and training $1M–$5M
Total full commercialization budget $12.5M–$44.3M
IP Strategy
Patentable Areas
Patent Area Value
Hydronic near-surface cooling pathway integrated with pressure redistribution Core technical claim
Opposed zone thermal control cool sacrum/back while warming feet Strong comfort and clinical differentiation
Pressurecycle recipes coordinated with thermal/humidity data Smartsurface control claim
Disposable coverlet over sealed thermalpressure overlay Infectioncontrol architecture
HeelFloat / CalfLift integrated thermalpressure accessory Heelspecific prevention system
Fluidingress detection beneath microclimate coverlet Safety and maintenance claim
RiskTrace protocol reporting Documentation and hospitalquality analytics
Retrofit overlay for existing Stryker beds Commercially important implementation claim
Manufacturing Strategy
Preferred Strategy
Phase 1–2 Contract prototype development with medical softgoods and medicaldevice engineering firms.
Phase 3 Pilot manufacturing under ISO 13485capable supplier.
Phase 4 License to Stryker or strategic partner for scaleup.
Phase 5 Retain royalty and R&D participation through Planting Foundations and Design Team Collaboration.
Why Licensing Is Preferred
Direct Manufacturing Licensing to Stryker
Requires high capital Lower capital requirement
Requires FDA and global regulatory infrastructure Partner already has infrastructure
Requires hospital sales force Stryker already has hospital channel
Requires service network Stryker already services beds and support surfaces
Higher profit potential but higher risk Lower risk, faster adoption
Harder to enter hospitals Easier through existing bed ecosystem
Sales Strategy
Hospital Sales Message
VitalSurface helps hospitals attack the hidden causes of pressure injury between repositioning intervals heat, moisture, pressure duration, heel loading, and friction.
ROI Message
A single avoided advanced pressure injury can justify the cost of multiple VitalSurface units. AHRQ reports individual care costs ranging from $20,900 to $151,700 per pressure ulcer, which creates a strong economic case for prevention. ([AHRQ][1])
Buyer Targets
Buyer Message
Chief Nursing Officer Reduce preventable harm and nursing burden
Woundcare director Better microclimate and pressurerisk control
ICU director Highrisk immobile patient protection
Biomedical engineering Serviceable, sealed, monitored support surface
Infection prevention Disposable coverlet and sealed barrier architecture
CFO / value analysis committee Avoided pressureinjury cost and liability
Risk management Prevention documentation and protocol compliance
Planting Foundations and Design Team Collaboration Integration
VitalSurface should be presented as both a medicaldevice opportunity and an innovation education platform.
Program Structure
Program Layer Role
Planting Foundations CareTech Lab Philanthropic R&D and education arm
Design Team Collaboration Engineering, prototyping, CAD, testing, documentation
Youth Biomedical Challenge Student design projects around pressure, heat, moisture, and elder care
Clinical Advisory Network Woundcare nurses, physicians, biomedical engineers
Licensing Revenue Share Funds future youth innovation, research, and prototype development
Impact Thesis
Innovation is philanthropy when it prevents suffering, reduces infection risk, lowers healthcare cost, improves elder care, and teaches the next generation to solve real human problems.
Risk Analysis
Risk Mitigation
Stryker already has advanced support surfaces Position as thermalintelligence extension, not replacement
Regulatory complexity Start with conservative claims and predicatedevice strategy
Fluid ingress / infection concern Disposable coverlet plus sealed reusable barrier
Cooling discomfort Separate foot warming and comfort override
Condensation risk Humidity sensors, dewpoint logic, thermal limits
Overclaiming prevention Build evidence progressively through trials
Cost sensitivity ICU premium first, then longtermcare and home versions
Manufacturing complexity License to established medicaldevice manufacturer
Nurse workflow resistance Simple presets, fast setup, easy cleaning
Patent overlap Focus on hydronic/thermalpressure coordination and sealed overlay architecture
Development Milestones
Milestone Target Outcome
M1 Provisional patent Protect core thermalpressurecoverlet architecture
M2 Engineering prototype Demonstrate cooling/warming, pressure cycling, and sealed cover system
M3 Bench validation Prove thermal control, pressure redistribution, leak resistance
M4 Clinical advisor review Confirm woundcare and nursing workflow value
M5 Stryker licensing package Pitch deck, prototype demo, IP summary, ROI model
M6 Pilot hospital study Generate microclimate, comfort, and safety data
M7 FDA submission if required Regulatory clearance pathway
M8 Strategic licensing agreement Upfront payment, milestones, royalty, educationfund share M9 Commercial launch Hospital adoption and postmarket evidence
Recommended GoTo Market Path
1. File provisional patents immediately around the hydronic microclimate overlay, disposable coverlet, opposed-zone thermal logic, pressurecycle coordination, and heel/calf accessory system.
2. Develop a bench prototype that visibly demonstrates cooling from calf/torso/sacral zones toward the upper body and warming at the feet.
3. Build a woundcare advisory board with ICU nurses, woundcare specialists, biomedical engineers, and longtermcare administrators.
4. Create a Stryker licensing package showing how VitalSurface strengthens, rather than competes with, Stryker’s current bed and supportsurface portfolio.
5. Run a small microclimate validation study measuring temperature, humidity, comfort, and pressure mapping.
6. Negotiate a strategic option agreement with Stryker or another major supportsurface company.
7. Use Planting Foundations / Design Team Collaboration as the philanthropic and educational R&D expansion model.
Final Business Positioning Statement
VitalSurface Microclimate Overlay is a smart medical supportsurface platform that transforms extended bed care by combining active hydronic cooling, footzone warming, alternating pressure redistribution, heel offloading, sealed infectioncontrol architecture, disposable microclimate coverlets, and protocol documentation into one Strykercompatible system.
The business opportunity is strongest as a licensable technology platform for Stryker or another major hospitalbed manufacturer. The product addresses a large, expensive, painful, and persistent healthcare problem while creating a highmargin hardware, disposablecoverlet, service, and datareporting opportunity.
The strategic market gap is clear
Current systems manage pressure and airflow. VitalSurface manages the entire skinbed interface.
